ArticleFrontiers in oncology2026
Association between pre-reversal systemic inflammation response index and low anterior resection syndrome in rectal cancer patients: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to explore the relationship between the systemic inflammation response index (SIRI) and the development of low anterior resection syndrome (LARS) in rectal cancer patients after ileostomy closure. Methods: This retrospective cohort study included 116 rectal cancer patients who underwent low anterior resection with diverting ileostomy and subsequent ileostomy reversal at the Fourth Hospital of Hebei Medical University between August 2022 and April 2024. SIRI was calculated from complete blood counts obtained within 1 week prior to ileostomy reversal. Postoperative bowel function was evaluated using the validated LARS questionnaire at 12 months after ileostomy closure. The association between SIRI and major LARS was examined using multivariable logistic regression models. A spline-based smooth curve fitting approach was applied to assess potential nonlinearity, and subgroup analyses were performed to explore effect modification across clinically relevant strata. Results: Among the 116 patients, 47 (40.5%) developed major LARS, while 69 (59.5%) had no or minor LARS. Compared to the no/minor LARS group, the major LARS group showed significantly higher SIRI levels (P = 0.011). Multivariate logistic regression analysis indicated that elevated SIRI was associated with a 295% increased risk of major LARS (OR: 3.95; 95% CI: 1.24, 12.61; P = 0.020). Subgroup analysis revealed that this association was more pronounced in patients with a lower anastomotic height (≤4 cm), younger age (≤60 years), shorter interval to stoma closure (Tertile 1), and those who did not receive adjuvant therapy. Conclusion: SIRI may become a biomarker for identifying patients at higher risk of developing severe LARS after rectal cancer surgery. Integrating SIRI into preoperative assessments could allow for early intervention and personalized management strategies to mitigate the severity of LARS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.